These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 8513188)
1. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors. Krasovec M; Elsner P; Burg G Dermatology; 1993; 186(4):248-52. PubMed ID: 8513188 [TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Hsu I; Spinler SA; Johnson NE Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093 [TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Lennernäs H; Fager G Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173 [TBL] [Abstract][Full Text] [Related]
4. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens. Mosley ST; Kalinowski SS; Schafer BL; Tanaka RD J Lipid Res; 1989 Sep; 30(9):1411-20. PubMed ID: 2513368 [TBL] [Abstract][Full Text] [Related]
5. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase. Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861 [TBL] [Abstract][Full Text] [Related]
6. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats. Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905 [TBL] [Abstract][Full Text] [Related]
7. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Masters BA; Palmoski MJ; Flint OP; Gregg RE; Wang-Iverson D; Durham SK Toxicol Appl Pharmacol; 1995 Mar; 131(1):163-74. PubMed ID: 7878672 [TBL] [Abstract][Full Text] [Related]
8. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. Serajuddin AT; Ranadive SA; Mahoney EM J Pharm Sci; 1991 Sep; 80(9):830-4. PubMed ID: 1800703 [TBL] [Abstract][Full Text] [Related]
9. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Kurakata S; Kada M; Shimada Y; Komai T; Nomoto K Immunopharmacology; 1996 Aug; 34(1):51-61. PubMed ID: 8880225 [TBL] [Abstract][Full Text] [Related]
10. [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias]. Carmena R Rev Esp Cardiol; 1995 Jan; 48(1):59-65. PubMed ID: 7878284 [No Abstract] [Full Text] [Related]
11. [Porphyria cutanea tarda induced by HMG CoA reductase inhibitors: simvastatin, pravastatin]. Perrot JL; Guy C; Bour Guichenez G; Amigues O; Servoz J; Cambazard F Ann Dermatol Venereol; 1994; 121(11):817-9. PubMed ID: 7631993 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of cholesterol synthesis and hepatic 3-hydroxy-3-methylglutaryl--CoA reductase in rats by simvastatin and pravastatin. Del Puppo M; Rauli S; Galli Kienle M Lipids; 1995 Nov; 30(11):1057-61. PubMed ID: 8569435 [TBL] [Abstract][Full Text] [Related]
15. Hypercholesterolaemia: simvastatin and pravastatin alter cholesterol metabolism by different mechanisms. Owens D; Collins P; Johnson A; Tighe O; Robinson K; Tomkin GH Biochim Biophys Acta; 1991 Apr; 1082(3):303-9. PubMed ID: 1903069 [TBL] [Abstract][Full Text] [Related]
16. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis. Alberts AW Cardiology; 1990; 77 Suppl 4():14-21. PubMed ID: 2073667 [TBL] [Abstract][Full Text] [Related]
17. Skin lesions due to treatment with simvastatin (Zocor). Feldmann R; Mainetti C; Saurat JH Dermatology; 1993; 186(4):272. PubMed ID: 8513195 [No Abstract] [Full Text] [Related]
18. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs. Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500 [TBL] [Abstract][Full Text] [Related]
19. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors. Newman A; Clutterbuck RD; Powles RL; Catovsky D; Millar JL Leuk Lymphoma; 1997 Feb; 24(5-6):533-7. PubMed ID: 9086443 [TBL] [Abstract][Full Text] [Related]
20. Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia. Illingworth DR; Bacon S Am J Cardiol; 1987 Oct; 60(12):33G-42G. PubMed ID: 3314447 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]